PRIMENENIE AMBROKSOLA V TERAPII RESPIRATORNYKh ZABOLEVANIY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Complex treatment of patients with respiratory diseases along with other pathogenetic therapy includes drugs that reduce the viscosity and elasticity of sputum. In inflammatory diseases of the respiratory system, removal of accumulating sputum from the respiratory tract is a major challenge. Synthetic mucolytics are the most effective drugs affecting sputum. However, representatives of this group have different properties. For example, the ambroxol acts as secretomotor agent: it is able to restore the mucociliary transport due to activation of the movement of the cilia. In addition, the mechanism of action of ambroxol is associated with the stimulation of tracheobronchial secretion with reduced viscosity due to changes in the chemistry of its mucopolysaccharides. A very important property of ambroxol and its derivatives is the ability to stimulate the production of surfactant, increasing its synthesis, secretion and inhibits the breakdown. Ambroxol potentiates the antibacterial effect of the major groups of antibiotics. In recent years, publications describing the anti-inflammatory and antioxidant properties of ambroxol are available.

Full Text

Restricted Access

About the authors

N. P Knyazheskaya

Email: kniajeskaia@mail.ru

References

  1. Cough. Understanding and treating a problem with many causes. American College of Chest Physicians, 2000.
  2. Овчаренко С.И. Кашель: этиология, диагностика, подходы к лечению. Consilium Medicum. 2006; 8(1): 552-57.
  3. Чучалин А.Г. Болезни органов дыхания. Медицинская газета. 2000; 43.
  4. Машковский М.Д. Лекарственные средства. Харьков: Торсинг, 1997.
  5. Новиков Ю.К., Белевский А.С. Муколитики в комплексном лечении ХОБЛ. Лечащий врач. 2001; 2: http://www.osp.ru/doctore/2001/02/062.htm
  6. Волков И.К., Лукина О.Ф., Тыло О.В., Кушелевская О.В. Место муколитической терапии в лечении хронических заболеваний легких у детей. Педиатрия. 2005; 7(1).
  7. Чучалин А.Г., Княжеская Н.П., Кравченко Н.Ю. Место муколитического препарата Лазолван (амброксол) в клинической практике. Русский медицинский журнал. 2005; 26: 1736-39.
  8. Княжеская Н.П., Чучалин А.Г. Обоснование выбора препарата для лечения кашлевого синдрома и заболеваний, сопровождающихся выделением мокроты. Русский медицинский журнал. 2007; 15(18): 1-4.
  9. Княжеская Н.П., Бобков Е.В. Отхаркивающие препараты в практике врача-интериста. Особенности препарата Лазолван (амброксол). Справочник поликлинического врача. 2012; 2: 43-7.
  10. Melillo G., Cocco G. Ambroxol decreases bronchial hyperreactivity. Eur. J. Respir. Dis. 1986; 69: 316-20.
  11. Bianchi M., Mantovani A., Erroi A., Dinarello C.A., Ghezzi P. Ambroxol inhibits interleukin 1 and tumor necrosis factor production in human mononuclear cells. Agents Actions. 1990; 31(3-4): 275-79.
  12. Gibbs B.F., Schmutzler W., Vollrath I.B. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm. Res. 1999; 48(2): 86-93.
  13. Su X., Wang L., Song Y., Bai C. Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensive Care Med. 2004; 30(1): 133-40.
  14. Peroni D.G., Moser S., Gallo G., et al. Ambroxol inhibits neutrophil respiratory burst activated by alpha chain integrin adhesion. Int. J. Immunopathol. Pharmacol. 2013; 26(4): 883-87.
  15. Wang Y., Su N.X., Chen Z.Q., Wang Z., Zhang S.F. Effects of Fengbaisan on the expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung tissue of rats with chronic obstructive pulmonary disease. Chin. J. Integr. Med. 2013 Nov 16. [Epub ahead of print].
  16. Spatola J., Poderoso J.J., Wiemeyer J.C., et al. Influence of ambroxol on lung tissue penetration of amoxicilin. Arzneimittelforschung. 1987; 37(8): 956-66.
  17. Neria J.P., Rubi E.G. Response to the combination of ambroxol/amoxicillin versus amoxicillin alone in patients with acute respiratory infections. Comparative study of antibiotic levels in bronchial mucus and plasma. Compend. Invest. Clin. Lat. Am. 1992; 12(1): 5-10.
  18. Braga P.C. Antibiotic penetrability into bronchical mucus: Pharmocokinetics and Clinical considerations. Curr. Therap. Res. 1991; 49(2): 300-27.
  19. Paganin F., Bouvet O., Chanez P., et al. Evaluation of the effects of ambroxol on the ofloxacin concentrations in bronchial tissues in COPD patients with infectious exacerbation. Biopharm. Drug Dispos. 1995; 16: 393-401.
  20. Gene R., Poderoso J.J., Corazza C., et al. Influence of Ambroxol on amoxycillin levels in broncho-alveolar lavage fluid. Arzneimittelforschung. 1987; 37(8): 967-68.
  21. Belal F.F., Sharaf El-Din M.K., El-Enany N.M., Saad S. Micellar liquid chromatographic method for the simultaneous determination of Levofloxacin and Ambroxol in combined tablets: Application to biological fluids. Chem. Cent. J. 2013; 7(1): 162. doi: 10.1186/1752-153X-7-162.
  22. Barsic B., Klinar I., Strugar-Suica J. Azithromycin in the treatment of acute exacerbation of chronic bronchitis: a meta-analysis, ICMASKO 6. Program and abstracts, Bologna, Italy, January 23-25. 2002: 189.
  23. Principi N., Zavattini G. Possibility of interaction among antibiotics and mucolytics in children. Int. J. Pharm. Res. 1986; 6(5): 369-72.
  24. Wiemeyer J.C.M. Influence of ambroxol on broncho-pulmonary levels of antibiotics. Arzneimittelforschung. 1981; 31(1): 974-76.
  25. Harnett J., Wilson J. Effectiveness of Azithromycin in patients with community-aquired pneumonia: an evidenced-based metaanalysis of randomised controlled trials. In: ICMASKO 6. Program and abstracts. Bologna, Italy, January 23-25, 2002: 177.
  26. Bonnetti P. Ambroxol plus amoxicillin versus amoxicillin alone in various respiratory tract infections. Investig. Medica Internacional. 1993; 20: 99-103.
  27. Peralta J., Poderoso J.J., Corazza C., et al. Ambroxol plus amoxicillin in the treatment of exacerbations of chronic bronchitis. Arzneimittelforschung. 1987; 37: 969-71.
  28. Chang C.C., Cheng A.C., Chang A.B. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst. Rev. 2012; 2: CD006088. doi: 10.1002/14651858.CD006088.pub3.
  29. Gao X., Huang Y., Han Y., Bai C.X., Wang G. The protective effects of Ambroxol in Pseudomonas aeruginosa-induced pneumonia in rats. Arch. Med. Sci. 2011; 7(3): 405-13.
  30. Ma Y.T., Tian Y.P., Su J.L., et al. Influence of ambroxol on paraquat-induced lung tissue injury and change of pulmonary surfactantassociated protein A in the experimental rats. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2006; 24(6): 348-51. Chinese.
  31. Kimya Y., Kucukkomurcu S., Ozan H., Uncu G. Antenatal ambroxol usage in the prevention of infant respiratory distress syndrome. Beneficial and adverse effects. Clin. Exp. Obstet. Gynecol. 1995; 22: 204-11.
  32. Laoag-Fernandez J.B., Fernandez A.M., Maruo T. Antenatal use of ambroxol for the prevention of infant respiratory distress syndrome. J. Obstet. Gynaecol. Res. 2000; 26: 307-12.
  33. Wauer R.R., Schmalisch G., Bohme B., Arand J., Lehmann D. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome. Eur. J. Pediatr. 1992; 151: 357-63.
  34. Weinmann H.-M. Ambroxol in paediatrics. Therapieworche. 1981; 31: 7940-47.
  35. Lee C.S., Jang Y.Y., Song J.S., et al. Ambroxol inhibits peroxynitrite-induced damage of alpha1-antiproteinase and free radical production in activated phagocytic cells. Pharmacol. Toxicol. 2002; 91(3): 140-49.
  36. Huang J., Xu J., Tian L., Zhong L. A thioredoxin reductase and/or thioredoxin system-based mechanism for antioxidant effects of ambroxol. Biochimie. 2014; 97: 92-103. [Epub 2013 Oct 5].
  37. Sanders A., Hemmelgarn H., Melrose H.L., et al. Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease. Blood Cells Mol. Dis. 2013; 51(2): 109-15. [Epub 2013 Apr 30].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies